Effect of Brivaracetam in Photosensitive Epileptic Subjects

A Placebo-controlled, Single-blind, Multi-center Study to Explore the Photoparoxysmal Response in Photosensitive Epileptic Subjects After One Single Oral Dose of Brivaracetam in Capsules.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00401648

Enrollment

Registered

2006-11-20

Start date

2002-09-30

Completion date

2003-06-30

Last updated

2009-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

POC, photosensitive, epileptic, brivaracetam, PPR, AED

Brief summary

to assess the effect of brivaracetam on the photoparoxysmal EEG response in photosensitive epileptic subjects

Interventions

DRUGBrivaracetam

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* epileptic subjects with generalized PPR

Exclusion criteria

* more than 2 concomitant antiepileptic drugs

Design outcomes

Primary

Measure	Time frame
Identify lowest single oral dose producing maximal decrease or suppression of intermittent photic stimulation (IPS)photoparoxysmal response (PPR) in photosensitive epileptic subjects pre-dose	—
post placebo during 24h and post brivaracetam for up to 72 h	—

Secondary

Measure	Time frame
Assess relationship between plasma concentrations and changes in photosensitivity frequency range, time of onset and duration of suppressing effect	—
Safety	—

Countries

France, Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026